The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

Back Bay Life Science Report

Contenido proporcionado por Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

1y ago 25:54

MP3•Episodio en casa

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:

Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
Deal structures and the BD side of ADCs, and their extended revenue generation potential
Where the field is headed, in terms of clinical, BD and commercial standpoints

Read and connect with our authors: The Transactional Landscape Of ADCs: A Payday for Payloads

28 episodios

#Fitness #Medicine #Bay Life Science Advisors #Jonathan P. Gertler #Biopharma #Investmentbanking #LifeSciences #Medtech